Login
From:
Forbes
(Uncensored)
subscribe
GSK Inks $1.5 Billion Deal For CureVac’s mRNA Bird Flu, COVID And Seasonal Flu Vaccines
https://www.forbes.com/sites/roberthart/2024/07/03/gsk-secures-mrna-vaccines-for-bird-flu-covid-and-seasonal-flu-from-struggling-biotech-curevac/
links
backlinks
Roast topics
Find topics
Find it!
mRNA specialist CureVac, which struggled to compete with the likes of Pfizer, Moderna and BioNTech, said it will focus on developing mRNA cancer vaccines and will cut 30% of its staff.
